Peter Ordentlich - Dec 1, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Dec 1, 2022
Transactions value $
-$466,638
Form type
4
Date filed
12/2/2022, 04:01 PM
Previous filing
Aug 26, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $24K +3.77K +1423.4% $6.35 4.04K Dec 1, 2022 Direct
transaction SNDX Common Stock Sale -$94.3K -3.77K -93.44% $25.01 265 Dec 1, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $25.7K +4.03K +1520% $6.38 4.29K Dec 1, 2022 Direct
transaction SNDX Common Stock Sale -$101K -4.03K -93.83% $25.01 265 Dec 1, 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $110K +17.2K +6490.57% $6.38 17.5K Dec 2, 2022 Direct
transaction SNDX Common Stock Sale -$431K -17.2K -98.48% $25.05 265 Dec 2, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -4.03K -100% $0.00* 0 Dec 1, 2022 Common Stock 4.03K $6.38 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -3.77K -100% $0.00* 0 Dec 1, 2022 Common Stock 3.77K $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -17.2K -100% $0.00* 0 Dec 2, 2022 Common Stock 17.2K $6.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.00 to $25.03.
F3 The sale prices ranged from $25.00 to $25.19.
F4 This option is fully vested.